Lymphatica Medtech was awarded the highly selective EIC Pilot - SME instrument Ph2 EU grant to bring its breakthrough lymphedema treatment system to market.

Lausanne, Switzerland, September 20, 2019

Lymphatica Medtech has been awarded 1.8 million Euro in SME Phase 2 for the excellence of their product innovation with expected large societal impact. The EIC (European Innovation Council) SME Instrument funding program is a very competitive process with 83 projects funded for 1765 proposals at the April 2019 call.

“Receiving such a recognition is a great source of motivation for our team. The financial support of 1.8 million euros can significantly speed-up our operations, while increasing the visibility during closing of our current fundraising,” says Marco Pisano, CEO and co-founder of Lymphatica Medtech.

Lymphedema is most commonly caused by the removal of, or damage to lymph nodes as a part of cancer treatment. These interventions locally disrupt the lymphatic system, with lymph accumulating in one or more limb, causing chronic local swelling, pain and recurrent infections, leading to a state of disability for the patient.

More than 100 million people are struggling with lymphedema around the world, but an effective treatment has not yet been developed. Our goal is to provide vascular doctors with a solution to effectively treat their patients, who can restore their health and life quality.

Lymphatica Medtech developed the Lymphatica - LymphoDrain implant, the world’s first implantable device for lymphedema treatment. With the LymphoDrain implant, the lymph accumulated in the limb is continuously re-circulated internally thanks to our micropump/catheter system, thus aiming at eliminating the swelling and at offering unprecedented benefits for patients.

The European grant will support company current efforts in bringing LymphoDrain to market. “Lymphatica’s team is thrilled to run the clinical trials necessary to demonstrate LymphoDrain effectiveness” says Valentina Triacca, COO and co-founder of Lymphatica Medtech.

“Lymphedema patients currently have to face countless hurdles in their daily life due to their condition and due to their obligation of wearing tight compression garments and bandages to manage it” emphasizes Marco Pisano, “and we are proud to provide an alternative solution which may allow them to drastically improve their daily life”.

About the EIC Pilot Accelerator (Previously SME Instrument Phase 2)

The EIC Pilot Accelerator is a public funding program funded by the European Union. The EU grant is for small and medium-sized enterprises with a relevant, sound and strategic business plan and the ambition to scale up internationally. In Phase 2, companies receive up to € 2.5 million to bring their innovation to the market, free coaching and support in commercialization.

More about SME Instruments

About the Lymphatica Medtech SA

Lymphatica Medtech SA is a Swiss medical device company founded in July 2017. It is a spin-off of the renowned Swiss Federal Institute of Technologies, Lausanne (EPFL – Ecole Polytechnique Fédérale de Lausanne) and of the Centre Hospitaliere Universitaire Vaudois (CHUV). Lymphatica Medtech provides a breakthrough innovation in Lymphedema treatment.

More about Lymphatica Medtech SA

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 873401